https://www.biopharmawatch.com/news/SNN/smith-nephew-evos-pelvic-plating-system-launch BiopharmaWatch en 2026-09-23T15:11:00.000Z Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management https://www.biopharmawatch.com/news/BMY/bms-joins-raap-rare-access-action-project BiopharmaWatch en 2026-09-23T14:01:00.000Z New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP https://www.biopharmawatch.com/news/CHRS/coherus-oncology-markets-biosimilar-assets BiopharmaWatch en 2026-09-23T13:30:00.000Z Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets https://www.biopharmawatch.com/news/NXGL/nexgel-announces-investor-update-call-details BiopharmaWatch en 2026-09-23T13:29:00.000Z NEXGEL Announces Dial-In Details for Investor Update Call https://www.biopharmawatch.com/news/TECH/bio-techne-merck-acquisition-approval BiopharmaWatch en 2026-09-23T13:20:00.000Z Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany https://www.biopharmawatch.com/news/HCTI/hcti-acquires-roboticom-industrial-automation BiopharmaWatch en 2026-09-23T13:17:00.000Z Healthcare Triangle Signs Letter of Intent to Pursue the Proposed Acquisition of Roboticom's Cutting-Edge Industrial Precision Robotics Automation Business https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-104-trial-expansion-spain-portugal BiopharmaWatch en 2026-09-23T13:17:00.000Z MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal https://www.biopharmawatch.com/news/BCDA/biocardia-fda-helix-pre-submission-update BiopharmaWatch en 2026-09-23T13:15:00.000Z BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-stifel-2026-forum BiopharmaWatch en 2026-09-23T13:00:00.000Z Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/AGL/agilon-health-springfield-clinic-partnership-expansion BiopharmaWatch en 2026-09-23T13:00:00.000Z agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO https://www.biopharmawatch.com/news/LIVN/livanova-third-quarter-2026-results-announcement BiopharmaWatch en 2026-09-23T13:00:00.000Z LivaNova to Announce Third-Quarter 2026 Results https://www.biopharmawatch.com/news/GCTK/lokahi-therapeutics-strategic-update-lt-100-ai2-platform BiopharmaWatch en 2026-09-23T13:00:00.000Z Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities https://www.biopharmawatch.com/news/MRK/merck-manuals-inform-patients-inflammatory-bowel-disease BiopharmaWatch en 2026-09-23T13:00:00.000Z Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease https://www.biopharmawatch.com/news/EHTH/ehealth-partners-bernieportal-choice-arrangements BiopharmaWatch en 2026-09-23T13:00:00.000Z eHealth Partners with BerniePortal to Provide Integrated CHOICE Arrangements for Employers and Brokers https://www.biopharmawatch.com/news/OPTH/optimi-health-psilocybin-production-phase-2-trial BiopharmaWatch en 2026-09-23T13:00:00.000Z Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply https://www.biopharmawatch.com/news/IRMD/iradimed-participate-roth-healthcare-conference BiopharmaWatch en 2026-09-23T13:00:00.000Z IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference https://www.biopharmawatch.com/news/BNGO/bionano-expands-ogm-testing-hematologic-cancers BiopharmaWatch en 2026-09-23T13:00:00.000Z Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies https://www.biopharmawatch.com/news/PALI/palisade-bio-expands-phase-2b-ascentra-uc-program BiopharmaWatch en 2026-09-23T12:45:00.000Z Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-1-31-million-offering BiopharmaWatch en 2026-09-23T12:37:00.000Z IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-portfolio-expansion BiopharmaWatch en 2026-09-23T12:35:00.000Z SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations https://www.biopharmawatch.com/news/VBIO/valion-appoints-dean-zikria-interim-ceo-leadership-transitions BiopharmaWatch en 2026-09-23T12:33:10.321Z Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions https://www.biopharmawatch.com/news/GRML/greenland-mines-doubles-mining-footprint-west-greenland BiopharmaWatch en 2026-09-23T12:30:00.000Z Greenland Mines Ltd. (NASDAQ: GRML) Applies to More than Double Mining Footprint in West Greenland https://www.biopharmawatch.com/news/TMO/thermo-fisher-gibco-cho-k1-catalog-panel-launch BiopharmaWatch en 2026-09-23T12:30:00.000Z Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-mexican-patent-annamycin BiopharmaWatch en 2026-09-23T12:25:00.000Z Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 https://www.biopharmawatch.com/news/AZN/polaris-rx-exclusive-distributor-astrazeneca-flumist-home BiopharmaWatch en 2026-09-23T12:10:00.000Z Polaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-sidharth-kapileshwar-corporate-development-officer BiopharmaWatch en 2026-09-23T12:05:00.000Z MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer https://www.biopharmawatch.com/news/TPST/tempest-appoints-nancy-freda-smith-board BiopharmaWatch en 2026-09-23T12:00:20.000Z Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors https://www.biopharmawatch.com/news/MGTX/meiragtx-appoints-alan-sebulsky-board-directors BiopharmaWatch en 2026-09-23T12:00:15.000Z MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors https://www.biopharmawatch.com/news/ADGM/adagio-medical-strategic-review-shareholder-value BiopharmaWatch en 2026-09-23T12:00:00.000Z Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-discovery-target-conference BiopharmaWatch en 2026-09-23T12:00:00.000Z Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA https://www.biopharmawatch.com/news/CORT/corcept-leadership-transition BiopharmaWatch en 2026-09-23T12:00:00.000Z Corcept Announces Planned Leadership Transition https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2027-earnings-release-date BiopharmaWatch en 2026-09-23T12:00:00.000Z McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date https://www.biopharmawatch.com/news/LXEO/apertura-gene-therapy-lexeo-therapeutics-friedreich-ataxia BiopharmaWatch en 2026-09-23T12:00:00.000Z Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia https://www.biopharmawatch.com/news/PRQR/proqr-appoints-ai-officers-strategic-advisor BiopharmaWatch en 2026-09-23T12:00:00.000Z ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor https://www.biopharmawatch.com/news/ANVS/annovis-partnership-weave-bio-nda-buntanetap-alzheimers BiopharmaWatch en 2026-09-23T12:00:00.000Z Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease https://www.biopharmawatch.com/news/ALT/altimmune-participate-stifel-cardiometabolic-forum BiopharmaWatch en 2026-09-23T12:00:00.000Z Altimmune to Participate in Stifel Cardiometabolic Forum https://www.biopharmawatch.com/news/LTRN/lantern-pharma-agentic-ai-drug-development-presentation BiopharmaWatch en 2026-09-23T11:45:00.000Z Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET https://www.biopharmawatch.com/news/DCGO/docgo-webinar-hicuity-health-acquisition-details BiopharmaWatch en 2026-09-23T11:35:00.000Z DocGo Announces Upcoming Webinar to Outline Vision and Details of the Pending Hicuity Health Acquisition https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-obesity-patent-filing BiopharmaWatch en 2026-09-23T11:33:00.000Z Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings https://www.biopharmawatch.com/news/IMCC/im-cannabis-acquires-space-defense-innovations BiopharmaWatch en 2026-09-23T11:30:00.000Z IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-clinical-data-symposium BiopharmaWatch en 2026-09-23T11:30:00.000Z Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease https://www.biopharmawatch.com/news/WVE/wave-life-sciences-phase-2a-trial-wve-007-tirzepatide-obesity BiopharmaWatch en 2026-09-23T11:30:00.000Z Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity https://www.biopharmawatch.com/news/BMEA/biomea-fusion-terminates-public-offering-securities BiopharmaWatch en 2026-09-23T11:03:00.000Z Biomea Fusion Announces Termination of Proposed Public Offering of Securities https://www.biopharmawatch.com/news/PBM/psyence-biomeds-strategic-ibogaine-investment BiopharmaWatch en 2026-09-23T11:00:19.000Z Psyence BioMed Announces Strategic Ibogaine Investment https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-patent-allowance-fsparin-fsgs BiopharmaWatch en 2026-09-23T11:00:00.000Z Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis https://www.biopharmawatch.com/news/GKOS/glaukos-launches-could-it-be-kc-campaign BiopharmaWatch en 2026-09-23T11:00:00.000Z Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-additional-funding-phase-3-development BiopharmaWatch en 2026-09-23T11:00:00.000Z Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development https://www.biopharmawatch.com/news/CTSO/cytosorbents-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-23T11:00:00.000Z CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/ROIV/roivant-proof-of-concept-imvt-1402-lupus-results BiopharmaWatch en 2026-09-23T11:00:00.000Z Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/ACIU/ac-immune-positive-results-vacsyn-phase-2-trial BiopharmaWatch en 2026-09-23T11:00:00.000Z AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 https://www.biopharmawatch.com/news/IMVT/immunovant-imvt-1402-cutanous-lupus-results BiopharmaWatch en 2026-09-23T11:00:00.000Z Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-positive-week-28-data-orka-001 BiopharmaWatch en 2026-09-23T11:00:00.000Z Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-23T11:00:00.000Z Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-eadv-congress-2026 BiopharmaWatch en 2026-09-23T11:00:00.000Z Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fda-approval-everolimus-tablets BiopharmaWatch en 2026-09-23T10:55:00.000Z ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-phase-iii-maveric-enrollment-expansion BiopharmaWatch en 2026-09-23T10:00:00.000Z Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy https://www.biopharmawatch.com/news/IONS/ionis-positive-interim-data-phase-3-imagination-study BiopharmaWatch en 2026-09-23T05:00:00.000Z Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) https://www.biopharmawatch.com/news/INNV/innovage-announces-pricing-secondary-offering-common-stock-selling-stockholders BiopharmaWatch en 2026-09-23T00:46:00.000Z InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders https://www.biopharmawatch.com/news/NUTX/nutex-health-dual-listing-nasdaq-texas BiopharmaWatch en 2026-09-22T22:50:00.000Z Nutex Health Approved for Dual Listing on Nasdaq Texas https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-correction-warrant-inducement BiopharmaWatch en 2026-09-22T22:14:00.000Z Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release https://www.biopharmawatch.com/news/GEHC/ge-healthcare-dividend-increase-q3-2026 BiopharmaWatch en 2026-09-22T21:25:00.000Z GE HealthCare announces cash dividend increase for third quarter of 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-shareholder-meeting-results-name-change BiopharmaWatch en 2026-09-22T21:00:00.000Z Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change https://www.biopharmawatch.com/news/DGX/quest-diagnostics-third-quarter-results-october-2026 BiopharmaWatch en 2026-09-22T20:28:00.000Z Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 https://www.biopharmawatch.com/news/INCY/incyte-eadv-2026-inflammation-autoimmunity-data BiopharmaWatch en 2026-09-22T20:23:00.000Z Riassunto: I dati di Incyte al Congresso dell'Accademia Europea di Dermatologia e Venereologia (EADV) sottolineano l'ampiezza del portafoglio Infiammazione e Autoimmunità di Incyte https://www.biopharmawatch.com/news/INCY/incyte-eadv-2026-data-presentation BiopharmaWatch en 2026-09-22T20:22:00.000Z Samenvatting: De gegevens van Incyte op het congres van de Europese Academie voor Dermatologie en Venereologie (EADV) bevestigen de breedte van Incyte's portfolio op het gebied van ontsteking en auto-immuniteit https://www.biopharmawatch.com/news/TLSI/trisalus-fda-clearance-trinav-advance BiopharmaWatch en 2026-09-22T20:15:00.000Z TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization https://www.biopharmawatch.com/news/DHR/danaher-third-quarter-2026-earnings-call BiopharmaWatch en 2026-09-22T20:15:00.000Z Danaher Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/MEDP/medpace-holdings-third-quarter-2026-results BiopharmaWatch en 2026-09-22T20:05:00.000Z Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-pascal-desroches-board BiopharmaWatch en 2026-09-22T20:05:00.000Z GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors https://www.biopharmawatch.com/news/INNV/innovage-secondary-offering-common-stock BiopharmaWatch en 2026-09-22T20:02:00.000Z InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders https://www.biopharmawatch.com/news/INAB/in8bio-sidoti-small-cap-conference-2026 BiopharmaWatch en 2026-09-22T20:00:00.000Z IN8bio to Present at Sidoti Small-Cap Virtual Conference https://www.biopharmawatch.com/news/NTHI/neonc-delivery-change-brain-cancer-equation BiopharmaWatch en 2026-09-22T18:52:00.000Z NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier https://www.biopharmawatch.com/news/ONMD/atropos-health-expands-evidence-network BiopharmaWatch en 2026-09-22T17:40:00.000Z Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development https://www.biopharmawatch.com/news/GRML/greenland-security-pact-reshapes-rare-earth-supply BiopharmaWatch en 2026-09-22T17:13:41.000Z Greenland Security Pact Reshapes the Race for Rare Earth Supply https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-warrant-inducement-transaction BiopharmaWatch en 2026-09-22T16:50:00.000Z Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results BiopharmaWatch en 2026-09-22T16:05:00.000Z Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results https://www.biopharmawatch.com/news/ENOV/enovis-sponsors-aaos-registry-program BiopharmaWatch en 2026-09-22T16:02:00.000Z Enovis becomes first multi-registry industry sponsor of AAOS Registry Program https://www.biopharmawatch.com/news/GRML/greenland-mines-applauds-formal-signing-u-s-denmark-greenland-security BiopharmaWatch en 2026-09-22T16:00:00.000Z Greenland Mines Applauds Formal Signing of U.S.-Denmark-Greenland Security Agreement at United Nations https://www.biopharmawatch.com/news/PFE/pfizer-webcast-november-3-conference-call BiopharmaWatch en 2026-09-22T14:00:00.000Z Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts https://www.biopharmawatch.com/news/TAK/takeda-esmo-2026-oncology-pipeline-progress BiopharmaWatch en 2026-09-22T13:30:00.000Z Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 https://www.biopharmawatch.com/news/RLAY/x-chem-phase-3-milestone-relay-therapeutics BiopharmaWatch en 2026-09-22T13:30:00.000Z X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-expands-parkinsons-platform-tanaist-agreement BiopharmaWatch en 2026-09-22T13:20:00.000Z Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement https://www.biopharmawatch.com/news/LGND/sydnexis-royalty-agreement-ligand-ryjunea BiopharmaWatch en 2026-09-22T13:02:00.000Z Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® https://www.biopharmawatch.com/news/TECH/bio-techne-customer-experience-center-duesseldorf BiopharmaWatch en 2026-09-22T13:00:00.000Z Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration https://www.biopharmawatch.com/news/AMGN/amgen-positive-topline-phase-3-results-dazodalibep-sjogrens BiopharmaWatch en 2026-09-22T13:00:00.000Z AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE https://www.biopharmawatch.com/news/OPTH/optimi-health-appoints-dr-michael-blough-cdo BiopharmaWatch en 2026-09-22T13:00:00.000Z Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-treatment BiopharmaWatch en 2026-09-22T12:55:18.000Z AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/RVMD/ampligen-role-pancreatic-cancer-treatment-fda-approval BiopharmaWatch en 2026-09-22T12:55:00.000Z AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-3-trial-nsclc-progress BiopharmaWatch en 2026-09-22T12:47:00.000Z MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-expands-commercial-reach-atropus-health BiopharmaWatch en 2026-09-22T12:40:00.000Z OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health https://www.biopharmawatch.com/news/PALI/palisade-bio-fda-clearance-ind-pali-2108-crohns-disease BiopharmaWatch en 2026-09-22T12:35:00.000Z Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD https://www.biopharmawatch.com/news/PLRZ/polyrizon-first-patient-nasarix-allergy-blocker BiopharmaWatch en 2026-09-22T12:33:00.000Z Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker https://www.biopharmawatch.com/news/SABS/sab-bio-present-sab-142-data-easd-2026 BiopharmaWatch en 2026-09-22T12:30:28.000Z SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes https://www.biopharmawatch.com/news/COCH/envoy-medical-new-patents-global-patent-portfolio BiopharmaWatch en 2026-09-22T12:30:00.000Z Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-world-narcolepsy-day-2026 BiopharmaWatch en 2026-09-22T12:30:00.000Z Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community https://www.biopharmawatch.com/news/GRML/ree-critical-metals-demand-western-nations-alternatives BiopharmaWatch en 2026-09-22T12:30:00.000Z REE, Critical Metals Demand Surging as Western Nations Race to Secure Alternatives https://www.biopharmawatch.com/news/INCY/incyte-eadv-congress-inflammation-autoimmunity-portfolio BiopharmaWatch en 2026-09-22T12:30:00.000Z Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio https://www.biopharmawatch.com/news/QTI/qt-imaging-honored-premier-supplier-innovation BiopharmaWatch en 2026-09-22T12:30:00.000Z QT Imaging to be Honored at Premier’s Annual Supplier Innovation Celebration https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-event-casdatifan-kidney-cancer BiopharmaWatch en 2026-09-22T12:30:00.000Z Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-data-eortc-nci-aacr-symposium BiopharmaWatch en 2026-09-22T12:30:00.000Z Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-regulatory-update-tovecimig-btc BiopharmaWatch en 2026-09-22T12:30:00.000Z Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-fast-track-qrx003-peeling-skin-syndrome BiopharmaWatch en 2026-09-22T12:30:00.000Z Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-cancer-data-eras-0015 BiopharmaWatch en 2026-09-22T12:30:00.000Z Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 https://www.biopharmawatch.com/news/SCNX/scienture-expands-rezenopy-distribution-addiction-centers BiopharmaWatch en 2026-09-22T12:15:00.000Z SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner https://www.biopharmawatch.com/news/RKTO/rocket-one-acquires-tracer-drone-technologies BiopharmaWatch en 2026-09-22T12:12:00.000Z Rocket One Signs Definitive Agreement to Acquire Revenue-Generating Tracer Drone Technologies, Accelerating AI and Counter-UAS Expansion Across Public Safety and Defense Markets https://www.biopharmawatch.com/news/VICP/vicapsys-reverse-merger-nitromist-acquisition BiopharmaWatch en 2026-09-22T12:05:00.000Z Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets https://www.biopharmawatch.com/news/IMNN/imunon-phase-2-mrd-study-imnn-001-update BiopharmaWatch en 2026-09-22T12:05:00.000Z IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-patent-advancements-australia-japan BiopharmaWatch en 2026-09-22T12:04:00.000Z TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology https://www.biopharmawatch.com/news/ADIA/adia-med-biologic-inventory-exceeds-1-5-million BiopharmaWatch en 2026-09-22T12:00:00.000Z Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products https://www.biopharmawatch.com/news/LNTH/lantheus-fda-approval-bravnetsa-gastroenteropancreatic-neuroendocrine-tumors BiopharmaWatch en 2026-09-22T12:00:00.000Z Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs https://www.biopharmawatch.com/news/NTRA/signatera-regulatory-approval-japan-bladder-cancer BiopharmaWatch en 2026-09-22T12:00:00.000Z Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-navref-2026 BiopharmaWatch en 2026-09-22T12:00:00.000Z bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference https://www.biopharmawatch.com/news/VRTX/vertex-positive-results-amplified-study-inaxaplin BiopharmaWatch en 2026-09-22T12:00:00.000Z Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial https://www.biopharmawatch.com/news/TRLV/trulieve-added-to-sp-indices BiopharmaWatch en 2026-09-22T12:00:00.000Z Trulieve Cannabis Corp. Added to S&P Total Market and S&P Completion Indices https://www.biopharmawatch.com/news/ENLV/enlivex-terminates-financing-rain-tokens BiopharmaWatch en 2026-09-22T12:00:00.000Z Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-fda-lift-clinical-hold-simufilam BiopharmaWatch en 2026-09-22T12:00:00.000Z Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-health-canada-approval-imcivree BiopharmaWatch en 2026-09-22T12:00:00.000Z Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity https://www.biopharmawatch.com/news/ADAG/adagene-nmpa-clearance-adg138-bispecific-engager BiopharmaWatch en 2026-09-22T12:00:00.000Z Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-manufacturing-support-kincellis-advanced-therapies BiopharmaWatch en 2026-09-22T12:00:00.000Z Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-steven-burke-board-directors BiopharmaWatch en 2026-09-22T12:00:00.000Z SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors https://www.biopharmawatch.com/news/SNN/smith-nephew-fda-clearance-landmark-knee-system BiopharmaWatch en 2026-09-22T12:00:00.000Z Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System https://www.biopharmawatch.com/news/IONS/ionis-ulefnersen-phase-3-fusion-trial-results BiopharmaWatch en 2026-09-22T12:00:00.000Z Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS https://www.biopharmawatch.com/news/CDRE/biocon-chmp-favorable-opinion-pertuzumab-biosimilar BiopharmaWatch en 2026-09-22T11:56:00.000Z Biocon obtient un avis favorable du CHMP pour son biosimilaire du pertuzumab, une première dans le cadre de la nouvelle approche clinique pour l'approbation des biosimilaires de l'EMA https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esoguard-esocheck-payment-advances BiopharmaWatch en 2026-09-22T11:55:00.000Z Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways https://www.biopharmawatch.com/news/LTRN/lantern-pharma-usppto-allowance-lp1284-patent BiopharmaWatch en 2026-09-22T11:45:00.000Z Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas https://www.biopharmawatch.com/news/RHEL/rhelion-life-sciences-new-canadian-patent-psilocybin BiopharmaWatch en 2026-09-22T11:33:00.000Z Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-pan-filovirus-program-fda-animal-rule BiopharmaWatch en 2026-09-22T11:30:00.000Z /C O R R E C T I O N -- Decoy Therapeutics, Inc/ https://www.biopharmawatch.com/news/CGC/canopy-growth-expands-uk-medical-cannabis-supply BiopharmaWatch en 2026-09-22T11:30:00.000Z Canopy Growth Expands European Medical Cannabis Supply Into the UK https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-pan-filovirus-fda-animal-rule BiopharmaWatch en 2026-09-22T11:30:00.000Z Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-sovargen-first-patient-phase-1b-2a-trial BiopharmaWatch en 2026-09-22T11:30:00.000Z Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders https://www.biopharmawatch.com/news/CRVO/cervomed-participate-5th-annual-roth-healthcare-opportunities-conference BiopharmaWatch en 2026-09-22T11:30:00.000Z CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference https://www.biopharmawatch.com/news/WVE/wave-life-sciences-appoints-dr-monika-vnuk-cbo BiopharmaWatch en 2026-09-22T11:30:00.000Z Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer https://www.biopharmawatch.com/news/CNSY/cerenome-secures-agreement-blue-cross-michigan BiopharmaWatch en 2026-09-22T11:30:00.000Z Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives https://www.biopharmawatch.com/news/BBNX/betabionics-senseonics-integration-ilet-eversense BiopharmaWatch en 2026-09-22T11:30:00.000Z Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-maintenance-study-results BiopharmaWatch en 2026-09-22T11:05:00.000Z Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-presentations-igg4-rd BiopharmaWatch en 2026-09-22T11:05:00.000Z Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-1000-pnp-tibia-nail-implantations BiopharmaWatch en 2026-09-22T11:05:00.000Z OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations https://www.biopharmawatch.com/news/JNJ/chmp-recommends-tecvayli-approval-johnson-johnson BiopharmaWatch en 2026-09-22T11:01:00.000Z Der CHMP empfiehlt die Zulassung von TECVAYLI®▼ (teclistamab) von Johnson & Johnson zur Behandlung des rezidivierten bzw. refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie https://www.biopharmawatch.com/news/MUSL/promino-reports-revenue-growth-kroger-distribution BiopharmaWatch en 2026-09-22T11:00:00.000Z Promino Reports Strength in Revenue as New Inventory and Kroger Distribution Drive Growth https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-study-results BiopharmaWatch en 2026-09-22T11:00:00.000Z Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society https://www.biopharmawatch.com/news/CSTL/castle-biosciences-new-laboratory-facility-scottsdale BiopharmaWatch en 2026-09-22T11:00:00.000Z Castle Biosciences to Open New Laboratory Facility in Scottsdale https://www.biopharmawatch.com/news/CGEN/compugen-virtual-kol-event-com701-ovarian-cancer-update BiopharmaWatch en 2026-09-22T11:00:00.000Z Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-edg-7500-mechanism-action BiopharmaWatch en 2026-09-22T11:00:00.000Z Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-medicare-agreement BiopharmaWatch en 2026-09-22T11:00:00.000Z Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-acquires-mantle-therapeutics BiopharmaWatch en 2026-09-22T11:00:00.000Z Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia https://www.biopharmawatch.com/news/MDWD/medi-wound-awarded-funding-nexobrid-development BiopharmaWatch en 2026-09-22T11:00:00.000Z MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® https://www.biopharmawatch.com/news/CLDX/celldex-positive-results-phase-3-barzolvolimab BiopharmaWatch en 2026-09-22T10:58:00.000Z Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints https://www.biopharmawatch.com/news/MRK/fda-approves-winrevair-label-update-hyperion-trial BiopharmaWatch en 2026-09-22T10:45:00.000Z U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) https://www.biopharmawatch.com/news/SMMT/harmoni-gi1-phase-iii-trial-esmo-2026 BiopharmaWatch en 2026-09-22T10:00:00.000Z HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026 https://www.biopharmawatch.com/news/JAGX/jaguar-health-fda-fee-waivers-2027 BiopharmaWatch en 2026-09-22T09:05:00.000Z Jaguar Health Receives Fee Waivers from FDA https://www.biopharmawatch.com/news/VOGX/vogenx-appoints-ken-toombs-board-directors BiopharmaWatch en 2026-09-22T09:00:00.000Z Vogenx Appoints Ken Toombs to Board of Directors https://www.biopharmawatch.com/news/STEK/stemtech-cornerstone-stem-cell-medicine BiopharmaWatch en 2026-09-22T08:30:00.000Z Physician Cites Stemtech as "Cornerstone" Behind His Focus on STEM Cell Medicine https://www.biopharmawatch.com/news/VBIO/valion-bio-regains-nasdaq-compliance BiopharmaWatch en 2026-09-22T08:00:00.000Z Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule https://www.biopharmawatch.com/news/ZOMDF/zomedica-partnership-vmg-veterinary-technologies BiopharmaWatch en 2026-09-22T06:00:00.000Z Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices https://www.biopharmawatch.com/news/ABBV/abbvie-eu-approval-rinvoq-pjia-treatment BiopharmaWatch en 2026-09-22T06:00:00.000Z AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis https://www.biopharmawatch.com/news/PHAR/pharming-leniolisib-positive-phase-ii-data-esid-2026 BiopharmaWatch en 2026-09-22T05:00:00.000Z Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 https://www.biopharmawatch.com/news/NVS/boomray-novartis-license-agreement-radioligand-therapy BiopharmaWatch en 2026-09-22T04:00:00.000Z BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset https://www.biopharmawatch.com/news/CYPH/cypherpunk-technologies-amanda-fabiano-board-appointment BiopharmaWatch en 2026-09-22T00:00:00.000Z Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), a privacy technology company, today announced the appointment of Amanda Fabiano to its... https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-td-cowen-summit-participation BiopharmaWatch en 2026-09-21T21:15:07.000Z Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit https://www.biopharmawatch.com/news/BDX/arthur-hu-joins-bd-as-chief-information-officer BiopharmaWatch en 2026-09-21T20:30:00.000Z Arthur Hu to Join BD as Chief Information and Digital Officer https://www.biopharmawatch.com/news/PTCT/ptc-acquisition-st-920-fabry-gene-therapy BiopharmaWatch en 2026-09-21T20:30:00.000Z PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-lytham-partners-fall-2026-conference BiopharmaWatch en 2026-09-21T20:30:00.000Z Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/ANAB/anaptysbio-q2-2026-financial-results-update BiopharmaWatch en 2026-09-21T20:15:00.000Z Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-ceo-transition BiopharmaWatch en 2026-09-21T20:05:00.000Z Travere Therapeutics Announces Planned Chief Executive Officer Transition https://www.biopharmawatch.com/news/ABVX/abivax-business-updates-first-half-2026-results BiopharmaWatch en 2026-09-21T20:05:00.000Z Abivax Presents Business Updates and First Half 2026 Financial Results https://www.biopharmawatch.com/news/NYXH/nyxoah-cfo-transition-2026 BiopharmaWatch en 2026-09-21T20:01:00.000Z Nyxoah Announces Chief Financial Officer Transition https://www.biopharmawatch.com/news/XENE/xenon-presents-td-cowen-summit BiopharmaWatch en 2026-09-21T20:01:00.000Z Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit https://www.biopharmawatch.com/news/NAMS/menarini-newamsterdam-eu-approval-ubeslo-evlarco BiopharmaWatch en 2026-09-21T19:04:00.000Z Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib) https://www.biopharmawatch.com/news/HYFT/mindwalk-openfold3-deployment-amd-vultr BiopharmaWatch en 2026-09-21T18:03:00.000Z MindWalk met OpenFold3 en production en quelques minutes grâce aux microservices d’inférence AMD sur Vultr Kubernetes Engine https://www.biopharmawatch.com/news/APP/applovin-securities-class-action-concerns-model-improvements BiopharmaWatch en 2026-09-21T16:31:00.000Z AppLovin (NASDAQ: APP) Faces Securities Class Action Amid Concerns Over Model Improvements -- HBSS https://www.biopharmawatch.com/news/FCEL/hagens-berman-fuelcell-energy-investors-class-action BiopharmaWatch en 2026-09-21T16:30:00.000Z HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FuelCell Energy, Inc. (NASDAQ: FCEL) Investors with Substantial Losses to Contact Firm https://www.biopharmawatch.com/news/AARD/aard-investor-notice-securities-fraud-class-action BiopharmaWatch en 2026-09-21T16:21:00.000Z AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-21T16:00:00.000Z Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum